116 related articles for article (PubMed ID: 3357653)
41. Plasma levels of estrogen, luteinizing hormone, and follicle stimulating hormone following castration and estradiol implant.
Hunter DJ; Julier D; Franklin M; Green E
Obstet Gynecol; 1977 Feb; 49(2):180-5. PubMed ID: 834401
[TBL] [Abstract][Full Text] [Related]
42. Effects of the dopamine antagonist veralipride on hot flushes and luteinizing hormone secretion in postmenopausal women.
Melis GB; Gambacciani M; Cagnacci A; Paoletti AM; Mais V; Fioretti P
Obstet Gynecol; 1988 Nov; 72(5):688-92. PubMed ID: 3140150
[TBL] [Abstract][Full Text] [Related]
43. Clinical and endocrine studies in menopausal women after estradiol pellet implantation.
Nagamani M; Lin TJ; McDonough PG; Watatani H; McPherson JC; Mahesh VB
Obstet Gynecol; 1977 Nov; 50(5):541-7. PubMed ID: 909658
[TBL] [Abstract][Full Text] [Related]
44. Efficacy and tolerability of Estraderm MX, a new estradiol matrix patch.
Bacchi-Modena A; Bolis P; Campagnoli C; De Cicco F; Meschia M; Pansini F; Pisati R; Hüls G
Maturitas; 1997 Jul; 27(3):285-92. PubMed ID: 9288701
[TBL] [Abstract][Full Text] [Related]
45. Comparison of steady state development and reduction of menopausal symptoms after oral or transdermal delivery of 17-β-estradiol in young healthy symptomatic menopausal women.
Rohr UD; Volko CD; Schindler AE
Horm Mol Biol Clin Investig; 2014 Jun; 18(3):123-36. PubMed ID: 25390008
[TBL] [Abstract][Full Text] [Related]
46. [A study of percutaneous absorption of estradiol and progesterone in absolute alcohol in postmenopausal women].
Madsen LG; Munck AM; Pedersen OD; Micic S; Nielsen J; Svenstrup B; Jensen HK
Ugeskr Laeger; 1989 Aug; 151(32):2026-30. PubMed ID: 2773122
[TBL] [Abstract][Full Text] [Related]
47. Clinical experience with transdermal estradiol in the treatment of the climacteric.
Utian WH
Minerva Endocrinol; 1989; 14(1):45-8. PubMed ID: 2543895
[TBL] [Abstract][Full Text] [Related]
48. Serum concentrations of 17beta-estradiol and estrone after multiple-dose administration of percutaneous estradiol gel in symptomatic menopausal women.
Brennan JJ; Lu Z; Whitman M; Stafiniak P; van der Hoop RG
Ther Drug Monit; 2001 Apr; 23(2):134-8. PubMed ID: 11294513
[TBL] [Abstract][Full Text] [Related]
49. Dose-response efficacy of a new estradiol transdermal matrix patch for 7-day application: a randomized, double-blind, placebo-controlled study. Italian Menopause Research Group.
Rovati LC; Setnikar I; Genazzani AR
Gynecol Endocrinol; 2000 Aug; 14(4):282-91. PubMed ID: 11075300
[TBL] [Abstract][Full Text] [Related]
50. Efficacy of Cimicifuga racemosa on climacteric complaints: a randomized study versus low-dose transdermal estradiol.
Nappi RE; Malavasi B; Brundu B; Facchinetti F
Gynecol Endocrinol; 2005 Jan; 20(1):30-5. PubMed ID: 15969244
[TBL] [Abstract][Full Text] [Related]
51. [Lynestrenol and allylestrenol in the therapy of postmenopausal hot flushes].
Barták A; Rozprávka M; Blovský J
Cesk Gynekol; 1992 Oct; 57(8):408-13. PubMed ID: 1473164
[TBL] [Abstract][Full Text] [Related]
52. [Vaginal estradiol and progesterone in climacteric therapy].
Pedersen OD; Jensen HK
Ugeskr Laeger; 1989 Aug; 151(32):2016-9. PubMed ID: 2672496
[TBL] [Abstract][Full Text] [Related]
53. A randomized comparison of nonoral estradiol delivery in postmenopausal women.
Stanczyk FZ; Shoupe D; Nunez V; Macias-Gonzales P; Vijod MA; Lobo RA
Am J Obstet Gynecol; 1988 Dec; 159(6):1540-6. PubMed ID: 3144919
[TBL] [Abstract][Full Text] [Related]
54. Efficacy and tolerability of Menorest 50 compared with Estraderm TTS 50 in the treatment of postmenopausal symptoms. A randomized, multicenter, parallel group study.
Pornel B; Genazzani AR; Costes D; Dain MP; Lelann L; Vandepol C
Maturitas; 1995 Nov; 22(3):207-18. PubMed ID: 8746878
[TBL] [Abstract][Full Text] [Related]
55. Randomized comparison of intranasal and transdermal estradiol.
Lopes P; Merkus HM; Nauman J; Bruschi F; Foidart JM; Calaf J
Obstet Gynecol; 2000 Dec; 96(6):906-12. PubMed ID: 11084176
[TBL] [Abstract][Full Text] [Related]
56. Effects of a brain-enhanced estrogen delivery system on tail-skin temperature of the rat: implications for menopausal hot flush.
Rahimy MH; Bodor N; Simpkins JW
Maturitas; 1991 Mar; 13(1):51-63. PubMed ID: 1907349
[TBL] [Abstract][Full Text] [Related]
57. Efficacy and tolerance of Menorest compared to Premarin in the treatment of postmenopausal women. A randomised, multicentre, double-blind, double-dummy study.
Studd JW; McCarthy K; Zamblera D; Burger HG; Silberberg S; Wren B; Dain MP; Le Lann L; Vandepol C
Maturitas; 1995 Sep; 22(2):105-14. PubMed ID: 8538478
[TBL] [Abstract][Full Text] [Related]
58. Hot flushes during Gn-RH analogue administration despite normal serum oestradiol levels.
Bider D; Ben-Rafael Z; Shalev J; Mashiach S; Serr DM; Blankstein J
Maturitas; 1989 Sep; 11(3):223-8. PubMed ID: 2512468
[TBL] [Abstract][Full Text] [Related]
59. Half-life of estradiol in postmenopausal women.
Ginsburg ES; Gao X; Shea BF; Barbieri RL
Gynecol Obstet Invest; 1998; 45(1):45-8. PubMed ID: 9473164
[TBL] [Abstract][Full Text] [Related]
60. Oral medroxyprogesterone in the treatment of postmenopausal symptoms.
Schiff I; Tulchinsky D; Cramer D; Ryan KJ
JAMA; 1980 Sep; 244(13):1443-5. PubMed ID: 6775094
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
